The most promising approach for developing curative therapies that eliminate the last tumor cell is through vaccination against the tumor. The immune
system, if properly stimulated and educated, is capable of eliminating every
last tumor cell. The concept of vaccine immunotherapy against cancer is
based on the body's natural defense system, which protects against a variety
of diseases. Vaccine immunotherapy has proven to be one of the most
effective treatment strategies for prevention of certain infectious
diseases. Vaccines using killed or attenuated pathogens have revolutionized
public health by preventing the development of many important infectious
diseases, including poliomyelitis, small pox, diphtheria, rabies, typhoid,
cholera, plague, measles, mumps, hepatitis B, diphtheria toxin and tetanus.
Application of these vaccination concepts to cancer could similarly
revolutionize cancer treatment.
However, attempts to develop cancer vaccines for treatment of existing
tumors have proven to be much more difficult than developing vaccines for
prevention of infectious diseases. Attempts to develop immunotherapies such
as cancer vaccines, despite many decades of experimental work, have yet to
consistently reach their curative potential in human clinical trials. |
 The one exception to the failure of immunotherapy protocols to produce significant anti-tumor effects in patients is the immune response that occurs in patients that undergo allergenic bone marrow/stem cell transplant procedures (BMT). BMT is a proven curative therapy for hematological malignancy and also has shown application for the treatment of solid tumors. The curative effect of BMT is mediated by transplanted immune cells derived from a normal (tissue matched) donor. The immune mediated anti-tumor effect of these transplanted immune cells is known as the graft vs. tumor (GVT) effect.
The GVT effect is the most powerful and most effective anti-tumor mechanism ever observed in the treatment of human malignancy. However, the same immune cells (primarily T-cells) which mediate GVT also mediate a serious and often lethal side effect known as graft vs. host disease (GVHD). This is due to the fact that the transplanted immune T-cells recognize both normal and tumor cells as foreign and mount attacks against both indiscriminately. Despite the curative effect of BMT, the severe treatment related toxicity has prevented the wide spread application of aBMT for cancer treatment. The powerful GVT immune response observed in BMT procedures is capable of overcoming tumor immunoavoidance mechanisms, resulting in complete systemic eradication of cancer in many instances. This GVT effect has been shown to be capable of curing patients with large tumor burdens, including patients with tumors unresponsive to chemotherapy, radiation and other forms of immunotherapy.
The Company’s products are based upon “Mirror Effect™” technology (patents pending) which is designed to provide the same anti-tumor effect that has been proven to be curative in allergenic bone marrow transplant (BMT) procedures without the lethal toxicity. |